FREMONT, Calif. — Shares of Alamar Biosciences Inc. surged 15.90% to $37.10 in Thursday trading, adding $5.09, pushing the precision proteomics company’s stock close to its 52-week high as investor interest continues building following a string of recent analyst upgrades, strategic partnerships and appearances at major healthcare investor conferences.

The rally lifts Alamar shares near the top of a 52-week trading range that has spanned from $17.00, the price at which the company priced its initial public offering in April, to a high of $38.54. Alamar debuted on the Nasdaq on April 20, with shares jumping 33% on their first day of trading and valuing the precision protein biomarker detection company at approximately $1.53 billion at the time. The company’s IPO raised roughly $219.9 million in gross proceeds after pricing 12.9 million shares, including the full exercise of the underwriters’ option, at $17 per share, the high end of its marketed range.

Alamar’s stock has continued to draw attention from Wall Street analysts in the months since its public debut. Leerink initiated coverage of the company with an Outperform rating and a $35 price target, with the firm’s thesis centered on what it described as Alamar’s differentiated, highly automated ARGO HT instrument and its underlying NULISA technology platform. Stifel more recently raised its own price target on Alamar shares to $32 from $28, according to recent analyst commentary, reflecting growing confidence in the company’s commercial trajectory even as the stock’s rapid appreciation has occasionally outpaced individual analyst targets.

Founded in 2018 and based in Fremont, California, Alamar Biosciences describes itself as a leader in precision proteomics dedicated to enabling the earliest possible detection of disease. The company’s core technology, known as NULISA, stands for Nucleic Acid Linked Immuno-Sandwich Assay, an ultrasensitive protein detection method the company has paired with its proprietary ARGO HT instrument to offer researchers and, eventually, clinicians a highly automated platform for identifying disease-related protein biomarkers at extremely low concentrations. The company has said it intends to pursue a path toward clinical diagnostic applications for the platform, with an FDA submission for an in vitro diagnostic system expected as soon as next year, part of a broader roadmap aimed at moving the technology beyond research use and into standard clinical practice.

That platform has found particularly strong early adoption within neurology and Alzheimer’s disease research. In August, Alamar announced an expanded global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures, under which a national-scale research initiative will use the company’s NULISAseq Neuro 220 panel to profile approximately 21,000 plasma samples collected from 10,000 participants with Alzheimer’s disease and related dementias. The company also launched its NULISAseq Immune 340 Panel in late July, expanding its product portfolio to offer more comprehensive profiling of the immune proteome for researchers studying immune-related conditions.

Alamar’s most recent quarterly results, reported August 10 alongside updated full-year 2026 revenue guidance, showed a sharp rise in revenue driven by accelerating demand for the company’s consumable testing products, alongside gross margin expansion the company attributed to improving operational scale. Those results helped fuel renewed investor interest in the stock even as the company continues to operate at a net loss typical of early-stage life sciences companies still investing heavily in research, development and commercial expansion.

The company presented at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, just days before Thursday’s sharp share price advance, an appearance that gave company executives an additional platform to update institutional investors on Alamar’s commercial progress and regulatory roadmap heading into the final months of the year.

Recent insider transactions at the company have also drawn attention amid the stock’s rally. Regulatory filings show General Counsel John Brottem received a restricted stock unit award and stock option grant on September 14, while newly appointed director Robert Ragusa, who joined Alamar’s board on September 1 and was named to the company’s Audit, Compensation, and Nominating and Corporate Governance Committees, received his own equity grants tied to his board appointment. Such routine compensation-related filings are common at newly public companies and do not typically reflect open-market buying or selling activity by company insiders.

Alamar’s market capitalization has climbed to approximately $1.94 billion in recent weeks, reflecting the stock’s substantial appreciation since its spring IPO. Trading volume in the stock has remained well above its historical daily average in recent sessions, a pattern often associated with heightened investor attention following news-driven catalysts, though no single company-specific announcement dated to Thursday’s session had been identified as the direct trigger for the day’s sharp gain as of the time of this report.

With Alamar continuing to expand its commercial partnerships in neurology and immunology research while advancing toward its stated goal of regulatory clearance for clinical diagnostic use, investors are likely to watch closely for further updates on the company’s progress toward that FDA submission, along with continued commercial traction for its expanding panel of research products, as key indicators of whether the stock’s recent rally can be sustained in the months ahead.

The proposed block deal is estimated to be worth Rs 2,047.40 crore. Platinum Jasmine is reportedly likely to sell the shares at Rs 682.45 apiece, which would represent a discount of up to 3.42% to Lenskart Solutions’ latest traded price of Rs 706.60 on the BSE. The seller is also reportedly subject to a 90-day lock-up period for any further sale of its stake.

As of June 30, 2026, Platinum Jasmine held 16,98,15,438 shares, representing a 9.77% stake in Lenskart Solutions, according to the company’s exchange filing.

At Friday’s closing price of Rs 706.60 per share, Lenskart Solutions shares ended 3.94% higher compared with the previous close of Rs 679.80. During Friday’s session, the stock traded in a range of Rs 677.50 to Rs 725 on the BSE.

ALSO READ: Adani stocks soar up to 12% after Jefferies sees up to 53% upside in Adani Energy and others

Live Events

Lenskart Solutions made its stock-market debut in November 2025 after raising Rs 7,278.02 crore through a combination of a fresh issue of 53.5 million equity shares and an offer for sale of up to 127.6 million shares by promoters and existing investors.
The company’s shares listed at Rs 395 apiece on the NSE, a 1.75% discount to the issue price of Rs 402. On the BSE, the shares opened at Rs 390, marking a 3% discount to the issue price.At Friday’s closing price of Rs 706.60, Lenskart shares were about 75.77% above their IPO issue price of Rs 402.

Earlier last month, on August 12, Lenskart Solutions reported a rise in profit after tax (PAT) to Rs 228 crore for the first quarter of FY27, compared with Rs 61 crore in the same quarter of the previous fiscal year.

Revenue from operations increased to Rs 2,714 crore during the quarter from Rs 1,894 crore in Q1 FY26.

EBITDA stood at Rs 589 crore, compared with about Rs 365 crore in the year-ago quarter.

About Lenskart Solutions

Lenskart Solutions is a tech-driven and integrated eyewear company primarily selling prescription eyeglasses, sunglasses and other products such as contact lenses and eyewear accessories.

The company sells its products in India, its largest market, and has recently expanded into select international markets such as Japan, Southeast Asia and the Middle East. Lenskart designs and sells a wide range of eyewear products under multiple owned in-house brands and sub-brands.

Disclosure: This article has been written by Kumar Gaurav, who is not a SEBI-registered Research Analyst or an investment advisor. Gaurav does not hold any financial interest in the company as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of the EconomicTimes Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment.

Investment banking giant JP Morgan has said it is struggling to predict how oil prices will be impacted by the US-Iran war, telling investors in a rare note that “we simply don’t know how to model the endgame”.

The bank said it assumed at the start of the conflict that there would be “economic red lines” that the Trump administration would be unwilling to cross, and therefore it believed a deal would have been struck to open up the Strait of Hormuz shipping lane back in June.

It said such red lines included oil prices rising above $100 a barrel, inflation reaching 4%, gasoline topping $5 a gallon and rates on 10-year government borrowing hitting 5%.

“The market is on edge,” analysts said.

JP Morgan is a huge name in the financial world, so for the investment bank to admit its experts are grappling with working out the economic impact of the US-Iran conflict reflects the tricky nature of trying to predict President Donald Trump’s next moves.

An oil and gas industry source told the BBC it was “unusual” for such a high-profile investment firm to issue such a note, but added it was a “reflection on the state of play”, given the uncertainties around the conflict.

Investors often make investment decisions on inflation expectations and the price of oil is a major factor in prices rising across the world, given the commodity’s widespread use and humanity’s dependence on it.

While gasoline remains below $5 and inflation has also not reached 4%, oil prices have surged back above $100 in recent weeks and the interest rate – known as a yield – on government bonds, which are issued in order for the US to borrow money from financial markets, has ticked over 5%.

“Six months later [since the war began], many of those lines have been crossed, yet the exit strategy is less clear, not more,” said the commodities research team at JP Morgan in note.

“For the first time since the start of the Iran conflict, we don’t have a baseline view. We simply don’t know how to model the endgame.”

Character.AI

Long before Elon Musk was running multiple companies at once, his mother, Maye Musk, had a much simpler recommendation: pick one.

Elon Musk’s mother, Maye Musk, joined FOX Business’ Stuart Varney on “Varney & Co.” to discuss her son’s ambitions, his childhood and the advice he ignored before taking on some of his biggest ventures.

Maye Musk reflects on her son Elon Musks’ ambitions and the advice he chose not to follow. (Tyler Boye/WWD/Penske Media / Getty Images)

Maye recalled a conversation with Elon after PayPal, when he was weighing what to pursue next.

“And that…came later after PayPal, when he said to me, should I do electric cars, or rockets, or solar energy? And I say, you’ve just worked so hard, just do one. So you see, he doesn’t listen to me,” Musk said.

SPACEX MAKES HISTORIC DEBUT; MUSK SOLIDIFIES STATUS AS WORLD’S FIRST TRILLIONAIRE

Instead, she said, her son went on to pursue several companies despite widespread doubts about whether they would succeed.

“And then he did six companies, and they were all going to fail. Remember? Everybody’s fail, fail, fail and now I’m so proud of him,” she said.

Maye said she noticed her son thought differently from an early age, recalling how he would become absorbed in deep thought as a young child before making observations that surprised her.

SPACEX UNVEILS $100B LOUISIANA LAUNCH SITE EXPECTED TO CREATE THOUSANDS OF JOBS

“He was different because he would go into deep thoughts,” she said, adding that he was making profound observations as young as three years old.

Looking back, Maye said her son’s ability to recognize, describe and figure things out was apparent when he was a child.

“He could recognize things, and he can describe it, and I was saying, ‘that’s three-year-old, you know. He can figure out things,’” she said.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Isao Kudo
GM of Investment & Asset Management Division I

My name is Kudo, and I’m from ITOCHU REIT Management. Thank you very much for watching this video on the financial results of Advance Residence Investment Corporation. I would also like to take this opportunity to extend my sincere appreciation to unitholders and all other stakeholders for your continued and invaluable support.

With that, I will now present the financial results for the fiscal period ended July 2026. Today, we will cover 6 themes in the following order: strategy and financial highlights, cash allocation and distribution outlook, internal growth, property acquisitions and dispositions, finance and sustainability. First, let’s look at strategy and financial highlights. There are no changes in management policy going forward. Through the 3 main pillars of internal growth, external growth and financial and capital strategy, the Investment Corporation will continue pursuing stable and sustainable distributions.

First is internal growth. We aim to achieve ongoing enhancements to the Corporation’s earnings power, primarily centered on rent growth. A key driver of this growth is the living room remodeling project. In addition to generating added value through remodeling, we also promote asset value enhancement initiatives that incorporate ESG perspectives. Next is external growth. We promote selective acquisitions through asset replacement. With an eye toward medium- to long-term growth, we will enhance the overall quality of the Corporation’s portfolio through asset replacement while steadily returning value to unitholders through gains on sales.

Now let’s look at the financial and capital strategy. The Corporation will maintain a solid foundation by balancing financial stability and financing flexibility while containing increases in financial costs. We will also

Macklemore’s removal from Ed Sheeran’s tour is having ripple effects on the ticket market.

Ticket prices for an upcoming Macklemore performance are climbing after the rapper was dropped from the remainder of Sheeran’s Loop tour for making pro-Palestine comments onstage earlier this month. Meanwhile, secondary market prices for the remainder of Sheeran’s concerts have dipped.

Resale prices for Macklemore’s October concert at Red Rocks in Colorado are increasing this week, even though the performance was announced in March.

“The get-in price [or the price for the cheapest available ticket] for that show is up 45% in the past 3 days, from $108 to $157,” Keith Pagello, founder of price tracking company TicketData, said in a statement to CNBC on Thursday. “That’s a surge we can say with confidence would not have happened absent this week’s events.”

Macklemore said on social media on Monday that he was removed from the tour after stadium owners threatened to cancel shows following his pro-Palestinian remarks during a performance at MetLife Stadium in New Jersey on Sept. 4. He announced on Thursday that he will donate his $1 million in earnings from the tour to Palestinian aid organizations.

All of Sheeran’s other supporting acts, Finneas, Aaron Rowe, Beoga and Lukas Graham, said they would leave the tour after Macklemore’s removal. It is unclear who will replace the performers.

Following the Macklemore headlines, ticket prices for Sheeran’s tour have decreased at nine of the ten remaining venues, according to TicketData which aggregates statistics from platforms including SeatGeek, Vivid Seats, Gametime, and StubHub.

However, Pagello said the drops are normal and may not be related to the controversy.

“Across the whole universe of concerts, more shows decline in price as the date approaches than rise,” Pagello said.

Ticket prices to Sheeran’s North American concerts this summer dropped by an average of 22% in the final two weeks leading up to the show, according to Pagello.

Pagello sees the amount of ticket resales to Sheeran’s upcoming concerts as more significant.

“There has been a clear uptick in resale volume: since Monday, tickets have been selling at a slight to moderately increased pace compared to earlier tour stops at the same distance out, even with prices trending down,” Pagello said.

While more tickets are changing hands, it’s unclear how much of the trend relates to opposition to Sheeran, support of him or other factors.

Sheeran maintained that Macklemore’s removal was the promoter’s decision and not his own in an Instagram post Wednesday. He also justified his decision to not speak publicly about his personal beliefs.

“I have always used my platform and music to bring people from all backgrounds and cultures together and this won’t ever change,” he wrote. “There is a reason I do not use my professional platform for politics – my audience includes young people, often children, of all backgrounds. Those who come to my shows do not expect a political forum.”

The concert promoting Sheeran’s eighth album “Play” kicked off late last year in New Zealand. The February leg in Australia was the high-grossing tour in the world that month, bringing in $70.8 million, according to Billboard.   

Sheeran has historically led some of the biggest tours in the world. His most recent tour, which wrapped last year, grossed $875.7 million and sold 8.8 million tickets, according to Billboard.